Join

Compare · ECOR vs LIVN

ECOR vs LIVN

Side-by-side comparison of electroCore Inc. (ECOR) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ECOR and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
  • LIVN is the larger of the two at $4.05B, about 50.1x ECOR ($81.0M).
  • Over the past year, ECOR is up 93.4% and LIVN is up 70.0% - ECOR leads by 23.4 points.
  • ECOR has been more active in the news (6 items in the past 4 weeks vs 4 for LIVN).
  • LIVN has more recent analyst coverage (20 ratings vs 2 for ECOR).
PerformanceECOR+93.40%LIVN+70.04%
2025-06-02+0.00%2026-05-29
MetricECORLIVN
Company
electroCore Inc.
LivaNova PLC
Price
$9.67+4.65%
$73.81+1.09%
Market cap
$81.0M
$4.05B
1M return
+54.60%
+25.32%
1Y return
+93.40%
+70.04%
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Exchange
NASDAQ
NASDAQ
IPO
2018
News (4w)
6
4
Recent ratings
2
20
ECOR

electroCore Inc.

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.

LIVN

LivaNova PLC

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

Latest ECOR

Latest LIVN